Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.
Artigas L, Coma M, Matos-Filipe P, Aguirre-Plans J, Farrés J, Valls R, Fernandez-Fuentes N, de la Haba-Rodriguez J, Olvera A, Barbera J, Morales R, Oliva B, Mas JM. Artigas L, et al. Among authors: mas jm. PLoS One. 2020 Oct 2;15(10):e0240149. doi: 10.1371/journal.pone.0240149. eCollection 2020. PLoS One. 2020. PMID: 33006999 Free PMC article.
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach.
Carcereny E, Fernández-Nistal A, López A, Montoto C, Naves A, Segú-Vergés C, Coma M, Jorba G, Oliva B, Mas JM. Carcereny E, et al. Among authors: mas jm. Oncotarget. 2021 Feb 16;12(4):316-332. doi: 10.18632/oncotarget.27875. eCollection 2021 Feb 16. Oncotarget. 2021. PMID: 33659043 Free PMC article.
Identification of the most vulnerable populations in the psychosocial sphere: a cross-sectional study conducted in Catalonia during the strict lockdown imposed against the COVID-19 pandemic.
Farrés J, Ruiz JL, Mas JM, Arias L, Sarrias MR, Armengol C, Cardona PJ, Munoz-Moreno JA, Vilaplana M, Arranz B, Usall J, Serrano-Blanco A, Vilaplana C. Farrés J, et al. Among authors: mas jm. BMJ Open. 2021 Nov 26;11(11):e052140. doi: 10.1136/bmjopen-2021-052140. BMJ Open. 2021. PMID: 34836903 Free PMC article.
Towards a molecular characterisation of pathological pathways.
Pache RA, Zanzoni A, Naval J, Mas JM, Aloy P. Pache RA, et al. Among authors: mas jm. FEBS Lett. 2008 Apr 9;582(8):1259-65. doi: 10.1016/j.febslet.2008.02.014. Epub 2008 Feb 20. FEBS Lett. 2008. PMID: 18282477 Free article. Review.
47 results